Volume 8, Issue 2 September 2014
New recommendations are being introduced to minimise the risk of serious hypersensitivity reactions with ferumoxytol. These include a contraindication in patients with any drug allergies and changes in the method of administration
Denosumab is associated with a risk of osteonecrosis of the jaw (ONJ) and with a risk of hypocalcaemia. Before starting denosumab treatment, a dental examination and appropriate preventive dentistry are now recommended to reduce the risk of osteonecrosis of the jaw (ONJ).
Nitrofurantoin is now contraindicated in patients with an estimated glomerular filtration rate (eGFR) of less than 45 ml/min. However, a short course (3 to 7 days) may be used with caution in certain patients with an eGFR of 30 to 44 ml/min.
MHRA's content will be moving to GOV.UK, the single website for the UK government.
This survey will be used as part of our user research for the Drug Safety Update